Online inquiry

IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15483MR)

This product GTTS-WQ15483MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15483MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13646MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ4123MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ6851MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ9275MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ5083MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ2745MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ8811MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ10092MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW